Literature DB >> 26635033

Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia.

Martin F M de Rooij1, Annemieke Kuil1, Willem Kraan1, Marie José Kersten2, Steven P Treon3, Steven T Pals4, Marcel Spaargaren5.   

Abstract

Entities:  

Keywords:  BCR; CXCR4; Waldenström macroglobulinemia; adhesion; kinase inhibitors

Mesh：

Substances：

Year:  2015        PMID： 26635033      PMCID： PMC4815740          DOI： 10.3324/haematol.2015.137265

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.

Authors:  Martin F M de Rooij; Annemieke Kuil; Christian R Geest; Eric Eldering; Betty Y Chang; Joseph J Buggy; Steven T Pals; Marcel Spaargaren
Journal:  Blood       Date:  2012-01-25       Impact factor: 22.113

2.  MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

Authors:  Steven P Treon; Lian Xu; Guang Yang; Yangsheng Zhou; Xia Liu; Yang Cao; Patricia Sheehy; Robert J Manning; Christopher J Patterson; Christina Tripsas; Luca Arcaini; Geraldine S Pinkus; Scott J Rodig; Aliyah R Sohani; Nancy Lee Harris; Jason M Laramie; Donald A Skifter; Stephen E Lincoln; Zachary R Hunter
Journal:  N Engl J Med       Date:  2012-08-30       Impact factor: 91.245

Review 3.  BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.

Authors:  M Spaargaren; M F M de Rooij; A P Kater; E Eldering
Journal:  Oncogene       Date:  2014-06-23       Impact factor: 9.867

4.  PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

Authors:  Ajay K Gopal; Brad S Kahl; Sven de Vos; Nina D Wagner-Johnston; Stephen J Schuster; Wojciech J Jurczak; Ian W Flinn; Christopher R Flowers; Peter Martin; Andreas Viardot; Kristie A Blum; Andre H Goy; Andrew J Davies; Pier Luigi Zinzani; Martin Dreyling; Dave Johnson; Langdon L Miller; Leanne Holes; Daniel Li; Roger D Dansey; Wayne R Godfrey; Gilles A Salles
Journal:  N Engl J Med       Date:  2014-01-22       Impact factor: 91.245

5.  Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.

Authors:  Ian W Flinn; Brad S Kahl; John P Leonard; Richard R Furman; Jennifer R Brown; John C Byrd; Nina D Wagner-Johnston; Steve E Coutre; Don M Benson; Sissy Peterman; Yoonjin Cho; Heather K Webb; David M Johnson; Albert S Yu; Roger G Ulrich; Wayne R Godfrey; Langdon L Miller; Stephen E Spurgeon
Journal:  Blood       Date:  2014-03-10       Impact factor: 22.113

6.  A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.

Authors:  Guang Yang; Yangsheng Zhou; Xia Liu; Lian Xu; Yang Cao; Robert J Manning; Christopher J Patterson; Sara J Buhrlage; Nathanael Gray; Yu-Tzu Tai; Kenneth C Anderson; Zachary R Hunter; Steven P Treon
Journal:  Blood       Date:  2013-07-08       Impact factor: 22.113

7.  WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12.

Authors:  Karl Balabanian; Bernard Lagane; José Luis Pablos; Lysiane Laurent; Thierry Planchenault; Olivier Verola; Celeste Lebbe; Delphine Kerob; Alain Dupuy; Olivier Hermine; Jean-François Nicolas; Véronique Latger-Cannard; Danièle Bensoussan; Pierre Bordigoni; Françoise Baleux; Françoise Le Deist; Jean-Louis Virelizier; Fernando Arenzana-Seisdedos; Françoise Bachelerie
Journal:  Blood       Date:  2004-11-09       Impact factor: 22.113

8.  Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Authors:  Ranjana H Advani; Joseph J Buggy; Jeff P Sharman; Sonali M Smith; Thomas E Boyd; Barbara Grant; Kathryn S Kolibaba; Richard R Furman; Sara Rodriguez; Betty Y Chang; Juthamas Sukbuntherng; Raquel Izumi; Ahmed Hamdy; Eric Hedrick; Nathan H Fowler
Journal:  J Clin Oncol       Date:  2012-10-08       Impact factor: 44.544

9.  Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.

Authors:  Betty Y Chang; Michelle Francesco; Martin F M De Rooij; Padmaja Magadala; Susanne M Steggerda; Min Mei Huang; Annemieke Kuil; Sarah E M Herman; Stella Chang; Steven T Pals; Wyndham Wilson; Adrian Wiestner; Marcel Spaargaren; Joseph J Buggy; Laurence Elias
Journal:  Blood       Date:  2013-08-12       Impact factor: 22.113

10.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245
View more
  15 in total

1.  CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib.

Authors:  Josephine M Vos; Nickolas Tsakmaklis; Christopher J Patterson; Kirsten Meid; Jorge J Castillo; Philip Brodsky; Tomas Ganz; Steven T Pals; Marie José Kersten; Lian Xu; Guang Yang; Steven P Treon; Zachary R Hunter
Journal:  Haematologica       Date:  2017-08-10       Impact factor: 9.941

Review 2.  Targeting B-cell receptor signaling in leukemia and lymphoma: how and why?

Authors:  John C Allen; Fatima Talab; Joseph R Slupsky
Journal:  Int J Hematol Oncol       Date:  2016-05-26

3.  TLR-mediated activation of Waldenström macroglobulinemia B cells reveals an uncoupling from plasma cell differentiation.

Authors:  Jennifer Shrimpton; Matthew A Care; Jonathan Carmichael; Kieran Walker; Paul Evans; Charlotte Evans; Ruth de Tute; Roger Owen; Reuben M Tooze; Gina M Doody
Journal:  Blood Adv       Date:  2020-06-23

4.  Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma.

Authors:  Robert F Cornell; Veronika Bachanova; Anita D'Souza; Kwang Woo-Ahn; Michael Martens; Jiaxing Huang; A Samer Al-Homsi; Saurabh Chhabra; Edward Copelan; Miguel-Angel Diaz; Cesar O Freytes; Robert Peter Gale; Siddhartha Ganguly; Mehdi Hamadani; Gerhard Hildebrandt; Rammurti T Kamble; Mohamed Kharfan-Dabaja; Tamila Kindwall-Keller; Hillard M Lazarus; David I Marks; Taiga Nishihori; Richard F Olsson; Ayman Saad; Saad Usmani; David H Vesole; Jean Yared; Tomer Mark; Yago Nieto; Parameswaran Hari
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-24       Impact factor: 5.742

5.  Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells.

Authors:  Aneel Paulus; Alak Manna; Sharoon Akhtar; Shumail M Paulus; Mayank Sharma; Marie V Coignet; Liuyan Jiang; Vivek Roy; Thomas E Witzig; Stephen M Ansell; John Allan; Richard Furman; Sonikpreet Aulakh; Rami Manochakian; Sikander Ailawadhi; Asher A Chanan-Khan; Taimur Sher
Journal:  Br J Haematol       Date:  2018-08-06       Impact factor: 6.998

6.  Case 01-2017 - Primary vitreoretinal lymphoma (PVRL): report of a case and update of literature from 1942 to 2016.

Authors:  Yujuan Wang; Dik S Cheung; Chi-Chao Chan
Journal:  Ann Eye Sci       Date:  2017-07-01

Review 7.  Targeting B cell receptor signalling in cancer: preclinical and clinical advances.

Authors:  Jan A Burger; Adrian Wiestner
Journal:  Nat Rev Cancer       Date:  2018-01-19       Impact factor: 60.716

8.  Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia.

Authors:  Cécile Tomowiak; Stéphanie Poulain; Charles Herbaux; Aurore Perrot; Béatrice Mahé; Pierre Morel; Thérèse Aurran; Olivier Tournilhac; Stéphane Leprêtre; Souad Assaad; Bruno Villemagne; Olivier Casasnovas; Delphine Nollet; Damien Roos-Weil; Sylvie Chevret; Véronique Leblond
Journal:  Blood Adv       Date:  2021-05-11

9.  Mature IgM-expressing plasma cells sense antigen and develop competence for cytokine production upon antigenic challenge.

Authors:  Pascal Blanc; Ludovic Moro-Sibilot; Lucas Barthly; Ferdinand Jagot; Sébastien This; Simon de Bernard; Laurent Buffat; Sébastien Dussurgey; Renaud Colisson; Elias Hobeika; Thierry Fest; Morgan Taillardet; Olivier Thaunat; Antoine Sicard; Paul Mondière; Laurent Genestier; Stephen L Nutt; Thierry Defrance
Journal:  Nat Commun       Date:  2016-12-07       Impact factor: 14.919

Review 10.  At the Bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer.

Authors:  Gary D Luker; Jinming Yang; Ann Richmond; Stefania Scala; Claudio Festuccia; Margret Schottelius; Hans-Jürgen Wester; Johann Zimmermann
Journal:  J Leukoc Biol       Date:  2020-10-26       Impact factor: 4.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.